Age‐related behavioural deficits in transgenic mice expressing the HIV‐1 coat protein gp120

Transgenic mice expressing HIV‐1 coat glycoprotein gp120 in brain glial cells were previously shown to display AIDS dementia‐like neuropathological changes and reduced hippocampal long‐term potentiation. In this report, neuromotor and cognitive performance in 3‐ and 12‐month‐old gp120‐expressing mice was compared with wildtype controls. Rotarod and cage activity measures showed no significant differences between transgenic animals and controls of either age. Open field activity was slightly altered in 12‐month‐old gp120 animals (reduced corner crossings and dwell in centre), but not in the 3‐month‐olds. Cognitive assessment using the Morris water maze showed unimpaired performance in 3‐month‐old mice during acquisition and (no‐platform) probe trials. In 12‐month‐old gp120 animals, escape latency and swimming velocity during the acquisition trials were significantly reduced, but performance improved at roughly the same rate as in control animals. However, the probe trials revealed a highly significant reduction in spatial retention in transgenic mice of this age. This demonstration of age‐dependent impairments in open field activity and spatial reference memory may relate to cognitive and neuromotor deficits seen in a proportion of HIV‐1‐infected individuals.

[1]  D. Alkon,et al.  Memory and long-term potentiation (LTP) dissociated: normal spatial memory despite CA1 LTP elimination with Kv1.4 antisense. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Morris,et al.  Impaired spatial learning after saturation of long-term potentiation. , 1998, Science.

[3]  David P Wolfer,et al.  Genetically modified mice and cognition , 1998, Current Opinion in Neurobiology.

[4]  L. Mucke,et al.  Transgenic mice with cerebral expression of human immunodeficiency virus type-1 coat protein gp120 show divergent changes in short- and long-term potentiation in CA1 hippocampus , 1998, Neuroscience.

[5]  Susumu Tonegawa,et al.  Synaptic plasticity, place cells and spatial memory: study with second generation knockouts , 1997, Trends in Neurosciences.

[6]  S. Tonegawa,et al.  The Essential Role of Hippocampal CA1 NMDA Receptor–Dependent Synaptic Plasticity in Spatial Memory , 1996, Cell.

[7]  L. Mucke,et al.  Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine , 1996, Brain Research.

[8]  Howard E. Gendelman,et al.  Dementia Associated with the Acquired Immunodeficiency Syndrome , 1995 .

[9]  L. Mucke,et al.  Protection against HIV-1 gp120-induced brain damage by neuronal expression of human amyloid precursor protein , 1995, The Journal of experimental medicine.

[10]  T. Yagi,et al.  Reduced hippocampal LTP and spatial learning in mice lacking NMDA receptor ε1 subunit , 1995, Nature.

[11]  Alcino J. Silva,et al.  Targeting learning , 1994, Trends in Neurosciences.

[12]  Alcino J. Silva,et al.  Impaired spatial learning in alpha-calcium-calmodulin kinase II mutant mice. , 1992, Science.

[13]  Alcino J. Silva,et al.  Deficient hippocampal long-term potentiation in alpha-calcium-calmodulin kinase II mutant mice. , 1992, Science.

[14]  L. Panlilio,et al.  Learning impairment following intracerebral administration of the HIV envelope protein gp120 or a VIP antagonist , 1992, Brain Research.

[15]  J. Sidtis,et al.  The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. , 1988, Science.

[16]  G. Collingridge.  The role of NMDA receptors in learning and memory , 1987, Nature.

[17]  R. Morris.  Developments of a water-maze procedure for studying spatial learning in the rat , 1984, Journal of Neuroscience Methods.

[18]  R N Walsh,et al.  The Open-Field Test: a critical review. , 1976, Psychological bulletin.

[19]  N W DUNHAM,et al.  A note on a simple apparatus for detecting neurological deficit in rats and mice. , 1957, Journal of the American Pharmaceutical Association. American Pharmaceutical Association.

[20]  S. Lipton.  Neuronal injury associated with HIV-1: approaches to treatment. , 1998, Annual review of pharmacology and toxicology.

[21]  S. Lipton,et al.  Neuronal injury associated with HIV-1 and potential treatment with calcium-channel and NMDA antagonists. , 1994, Developmental neuroscience.

[22]  L. Mucke,et al.  Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. , 1994, Nature.

[23]  G. Lynch,et al.  Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5 , 1986, Nature.